ArticleClinical ophthalmology (Auckland, N.Z.)2026
Efficacy and Safety of 0.3% Preservative-Free Hyaluronic Acid-Based Eye Drops for the Management of Moderate to Severe Dry Eye Disease: A Prospective, Multicenter, Clinical Investigation.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Dry eye disease (DED) is a prevalent and chronic condition with multifactorial etiology. This study evaluated the efficacy and safety of a isotonic, preservative-free 0.3% hyaluronic acid (HA)-based ophthalmic solution (BLUgel A free), in patients with moderate-to-severe DED. Patients and Methods: This multicenter, prospective, post-market investigation enrolled 51 patients receiving HA eye drops. Most participants had comorbidities and were on polytherapy. Outcomes included changes in NEI grading scale, tear-film break-up time (TFBUT), Schirmer's test I, IDEEL questionnaire scores, non-invasive Break-Up Time (niBUT), tear meniscus height, conjunctival hyperaemia and meibography, assessed at 30 and 60 days. Results: A significant improvement in ocular surface integrity was observed throughout the study period. The NEI score decreased markedly from 8.38 ± 2.17 at baseline to 4.04 ± 2.93 after 30 days and further to 3.60 ± 3.30 at 60 days. Tear-film stability also improved, with TFBUT increasing significantly from 3.65 seconds at baseline to 6.51 seconds on day 30, and 7.26 seconds on day 60. Tear production, assessed by Schirmer's test, increased from 5.70 ± 2.82 mm to 8.74 ± 3.94 mm and then to 9.62 ± 4.57 mm over the same period. Patient-reported outcomes reflected these clinical improvements: IDEEL symptoms-bother scores dropped from 58.82 ± 10.57 to 40.99 ± 11.09, surpassing the clinically meaningful threshold of 12 points. Safety was confirmed, with only one minor adverse event (blurred vision) reported. Conclusion: 0.30% HA-based eye drops proved to be an effective and well-tolerated treatment for moderate-to-severe DED, offering clinical benefits even in patients receiving concomitant systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.